Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mydecine Innovations Group Inc (OP: MYCOF )

0.0037 UNCHANGED
Streaming Delayed Price Updated: 3:23 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Mydecine Innovations Group Inc

< Previous 1 2 3 4 5 6 7 Next >
Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Marks a Major Step in Seamless Phase 2/3 Smoking Cessation Clinical Trial; Partners with Combat Stress to Treat PTSD among Veterans
Via Investor Brand Network
BioMedNewsBreaks – Mydecine Innovations Group Inc.’s (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Exclusive Dealer Identified as Supplier for Health Canada’s Special Access Program
Via Investor Brand Network
Topics Supply Chain
Exposures Supply Chain
Mydecine Innovations Group develops novel compounds for treating mental health
Via AB Newswire
BioMedNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Strengthens Board with Appointment of Dr. Victoria Hale
Via Investor Brand Network
Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Clinical LOI to Further Use of Psychedelic Therapeutics in Treating Mental Illnesses
Via Investor Brand Network
PsychedelicNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) at the Forefront of Research Investigating Psilocybin Compound for Smoking Cessation
Via Investor Brand Network
Exposures Product Safety
PsychedelicNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) Bringing Safer, More Effective Nicotine Dependence Treatment to Market
Via Investor Brand Network
Mydecine Innovations Group Inc.’s (NEO: MYCO) (OTC: MYCOF) Plans Program to Provide Resources for Safe, Effective Integration of Psychedelic-Assisted Psychotherapies into Existing Medical Practices
Via Investor Brand Network
BioMedNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Announces Partnership to Treat PTSD in Veterans
Via Investor Brand Network
Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) to Launch Specialized Psychedelic Program in Canada
Via Investor Brand Network
PsychedelicNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), The Newly Partner to Set the Gold Standard for Psychedelic-Assisted Therapies
Via Investor Brand Network
PsychedelicNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Launches Canadian Program to Support Psychedelic-Assisted Psychotherapy
Via Investor Brand Network
BioMedNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Featured in Latest Episode of Bell2Bell Podcast
Via Investor Brand Network
Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: ONFA) Announces Completion of Target-Based Model in Its AI-Driven Drug Discovery Program
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence
BioMedNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Engages JBN Partners LLC, Completes Target-Based Model for AI-Driven Drug Discovery Program
Via Investor Brand Network
BioMedNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NF.F) Featured on ‘Gamechangers LIVE’
Via Investor Brand Network
Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Entering 2022 With Multiple Clinical Trials Including MYCO-001 for Smoking Cessation
Via Investor Brand Network
Topics Death
Exposures Death
Year-End Summary: Marijuana & Psychedelic Compounds-Based Drug Stocks Index Went DOWN -33.6% In 2021!
Which index performed the best in 2021, the Marijuana Drug Stocks Index, or the Psychedelic Compounds-Based Drug Stocks Index? Which constituents contributed to their performances? This article has the... 
Via Talk Markets
BioMedNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) Expanding Robust Portfolio of Novel Compounds
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Steep Decline In Cannabis & Psychedelic Compounds-Based Drug Stocks Continues: DOWN -16.6% MTD
All 12 constituents in the Marijuana & Psychedelic Compounds-Based Drug Stocks Index continue to decline. How do their performances compare month-to-date and YTD? 
Via Talk Markets
BioMedNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF), Maya to Collaborate in Development of Novel DTx Platform
Via Investor Brand Network
The Year In Review For Psychedelic Drug Stocks: 2021
2021 was two different 
Via Talk Markets
PsychedelicNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Standing Distinct in Advancing Psychedelic Medicine
Via Investor Brand Network
Topics Cannabis Intellectual Property
Exposures Cannabis Intellectual Property
Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), an Undervalued Opportunity for Investment
Via Investor Brand Network
Marijuana & Psychedelic Compounds-Based Drug Stocks Now Down -16% YTD
A look at which index has done the best so far in December: the Marijuana Drug Stocks Index or the Psychedelic Compounds-Based Drug Stocks Index. 
Via Talk Markets
Mind Medicine to Study Effect of Time on LSD Microdosing
Mind Medicine (NASDAQ: MNMD), a psychedelic medicine biotech company, plans to conduct research on how the time of the day during which an individual consumes microdoses of a... 
Via Benzinga
Mind Medicine (NASDAQ: MNMD) (NEO: MMED) to Study Effect of Time on LSD Microdosing
Via Investor Brand Network
Why Some Psychedelic Assisted Therapy Clinics Are Turning To Artificial Intelligence for Digital Mental Therapies
Palm Beach, FL –December 16, 2021 – FinancialNewsMedia.com News Commentary – Drugs like ketamine and psilocybin — the active ingredient in magic mushrooms — are showing real promise in addressing... 
Via FinancialNewsMedia
Topics Artificial Intelligence
Exposures Artificial Intelligence
Cannabis & Psychedelic Compound-Based Drug Stocks Continue To Decline
The six marijuana-based clinical-stage stocks are down 31.1% since the end of June; the 9 psychedelic compound-based clinical-stage stocks with market caps under $1B are down 36.3% in that same... 
Via Talk Markets
Topics Cannabis
Exposures Cannabis
Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) New Patent Application Offering Improved Delivery Control, Enhanced Shelf Stability, of Psilocin
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.